Orchestra BioMed (NASDAQ:OBIO - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at B. Riley Financial in a research note issued on Friday, Benzinga reports. They presently have a $12.00 target price on the stock, up from their prior target price of $11.00. B. Riley Financial's price objective points to a potential upside of 73.26% from the company's current price.
A number of other research analysts also recently weighed in on OBIO. Piper Sandler restated an "overweight" rating on shares of Orchestra BioMed in a research report on Thursday, October 15th. BTIG Research lifted their target price on shares of Orchestra BioMed from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, November 13th. HC Wainwright lifted their target price on shares of Orchestra BioMed from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, November 13th. Wall Street Zen upgraded shares of Orchestra BioMed from a "sell" rating to a "hold" rating in a research note on Saturday, November 14th. Finally, Weiss Ratings raised Orchestra BioMed from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 10th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.43.
Get Our Latest Stock Report on Orchestra BioMed
Orchestra BioMed Stock Performance
OBIO traded down $0.07 during midday trading on Friday, hitting $6.93. 68,681 shares of the company traded hands, compared to its average volume of 306,813. The company has a quick ratio of 7.24, a current ratio of 7.25 and a debt-to-equity ratio of 4.58. The firm has a market capitalization of $425.60 million, a PE ratio of -9.17 and a beta of 0.56. The company's 50-day moving average is $6.00 and its 200 day moving average is $4.69. Orchestra BioMed has a 52 week low of $3.46 and a 52 week high of $7.82.
Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.10. Orchestra BioMed had a negative net margin of 182.50% and a negative return on equity of 186.93%. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million. On average, research analysts expect that Orchestra BioMed will post -1.43 EPS for the current year.
Insider Transactions at Orchestra BioMed
In other news, Director Eric Fain purchased 20,000 shares of the business's stock in a transaction on Monday, November 9th. The stock was acquired at an average cost of $5.00 per share, for a total transaction of $100,000.00. Following the purchase, the director directly owned 119,630 shares in the company, valued at $598,150. This trade represents a 20.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Darren Sherman sold 15,000 shares of the company's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $5.74, for a total transaction of $86,100.00. Following the sale, the insider directly owned 1,104,402 shares of the company's stock, valued at $6,339,267.48. The trade was a 1.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders acquired 58,000 shares of company stock valued at $288,560 and sold 45,000 shares valued at $255,600. Insiders own 7.50% of the company's stock.
Institutional Trading of Orchestra BioMed
Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Orchestra BioMed in the second quarter worth approximately $10,832,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Orchestra BioMed during the 2nd quarter valued at $2,771,000. Goldman Sachs Group Inc. grew its position in shares of Orchestra BioMed by 112.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 382,160 shares of the company's stock valued at $2,377,000 after acquiring an additional 202,554 shares during the period. Rice Hall James & Associates LLC bought a new stake in shares of Orchestra BioMed during the 2nd quarter valued at $1,830,000. Finally, Flat Footed LLC purchased a new stake in shares of Orchestra BioMed in the 2nd quarter worth $1,084,670. 53.20% of the stock is currently owned by institutional investors.
About Orchestra BioMed
(
Get Free Report)
Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company's lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Orchestra BioMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.
While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.